Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lifecore BiomedicalLFCR 52 EV-to-EBIT is -47.48 as of Jul. 28, 2026. GuruFocus rates LFCR with a GF Score™ of 52/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 691 Drug Manufacturers companies, Lifecore Biomedical ranks worse than 144717.66% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lifecore Biomedical's Enterprise Value for the quarter that ended in Mar. 2026 was $267.36 Mil.
Lifecore Biomedical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical EV-to-EBIT Related Terms
Lifecore Biomedical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's EV-to-EBIT falls into.
Lifecore Biomedical's current Enterprise Value is $290.74 Mil.
Lifecore Biomedical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a EV-to-EBIT of -47.48 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lifecore Biomedical and its competitors. According to the industry distribution chart, Lifecore Biomedical ranks #999999 out of 691 companies in the Drug Manufacturers industry.
Is Lifecore Biomedical's EV-to-EBIT too high?
Lifecore Biomedical's current EV-to-EBIT is -47.48. Based on the distribution chart, Lifecore Biomedical ranks #999999 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's EV-to-EBIT compare to DERM and ADCT?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #999999 out of 691 companies for EV-to-EBIT. This places Lifecore Biomedical in the lower half of its industry. The industry median EV-to-EBIT is 15.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current EV-to-EBIT is -47.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $4.34 — trading 32.8% below its estimated fair value. The current EV-to-EBIT is -47.48. Lifecore Biomedical's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current EV-to-EBIT is -47.48 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.34 is trading 32.8% below its estimated GF Value™ of $6.46.
GuruFocus considers Lifecore Biomedical to be Possible Value Trap.
Key valuation signals for LFCR:
EV-to-EBIT: -47.48
GF Value™: $6.46 vs. price of $4.34 (32.8% below fair value)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
52GF Score
Get the complete analysis for LFCR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
